SCHEMBL7081133

SCHEMBL7081133

Cc1nn(C)c2ncc(N(C=O)C(=O)Nc3cccc(Oc4ccccc4)c3)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 3/20 0.44
MAPT P10636 2/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
SPR P35270 3/20 0.40
POLB P06746 2/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
NPY5R Q15761 1/20 0.40
FLT3 P36888 1/20 0.40
CCR2 P41597 3/20 0.39
CCR5 P51681 3/20 0.39
MITF O75030 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5961572 0.90 CCR2 (0.49) NR3C1MAPTMEN1KMT2APDE4A
SCHEMBL7078734 0.89 POLB (0.41) NR3C1MAPTPDE4APDE4BPDE4C
SCHEMBL7079006 0.86 MEN1 (0.45) NR3C1MAPTRAB9AMEN1NPC1
SCHEMBL7078063 0.86 SPR (0.40) NR3C1MAPTRAB9ANPC1SMN1; SMN2
SCHEMBL7075366 0.84 PDE4A (0.49) NR3C1MAPTRAB9AMEN1NPC1
SCHEMBL7077952 0.84 SPR (0.48) NR3C1RAB9AKMT2ASPRPOLB
SCHEMBL5961440 0.83 TP53 (0.47) NR3C1MAPTRAB9AMEN1KMT2A
SCHEMBL7074009 0.82 NR3C1 (0.48) NR3C1RAB9AMEN1NPC1KMT2A
SCHEMBL7079264 0.82 NR3C1 (0.40) NR3C1SPRPOLBCCR2CCR5
SCHEMBL3260025 0.81 SPR (0.46) NR3C1MAPTRAB9AMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6670364-B2 For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases TELIK, INC. 2003-12-30 US claimed
US-20030096705-A1 Antagonists of MCP-1 function and methods of use thereof SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 2003-05-22 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096705-A1 Antagonists of MCP-1 function and methods of use thereof CCR2, CCR1, CCL2 NR3C1 673/4885MAPT 2191/4885RAB9A 3364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.